Cargando…

In Vitro Activity of New β-Lactamase Inhibitor Combinations against bla(NDM), bla(KPC), and ESBL-Producing Enterobacteriales Uropathogens

Antibiotic resistance in uropathogens has increased substantially and severely affected treatment of urinary tract infections (UTIs). Lately, some new formulations, including meropenem/vaborbactam (MEV), ceftazidime/avibactam (CZA), and ceftolozane/tazobactam (C/T) have been introduced to treat infe...

Descripción completa

Detalles Bibliográficos
Autores principales: Razaq, Lubna, Uddin, Fakhur, Ali, Shahzad, Abbasi, Shah Muhammad, Sohail, Muhammad, Yousif, Nabila E., Abo-Dief, Hala M., El-Bahy, Zeinhom M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604030/
https://www.ncbi.nlm.nih.gov/pubmed/37887182
http://dx.doi.org/10.3390/antibiotics12101481
_version_ 1785126738153439232
author Razaq, Lubna
Uddin, Fakhur
Ali, Shahzad
Abbasi, Shah Muhammad
Sohail, Muhammad
Yousif, Nabila E.
Abo-Dief, Hala M.
El-Bahy, Zeinhom M.
author_facet Razaq, Lubna
Uddin, Fakhur
Ali, Shahzad
Abbasi, Shah Muhammad
Sohail, Muhammad
Yousif, Nabila E.
Abo-Dief, Hala M.
El-Bahy, Zeinhom M.
author_sort Razaq, Lubna
collection PubMed
description Antibiotic resistance in uropathogens has increased substantially and severely affected treatment of urinary tract infections (UTIs). Lately, some new formulations, including meropenem/vaborbactam (MEV), ceftazidime/avibactam (CZA), and ceftolozane/tazobactam (C/T) have been introduced to treat infections caused by drug-resistant pathogens. This study was designed to screen Enterobacteriales isolates from UTI patients and to assess their antimicrobial resistance pattern, particularly against the mentioned (new) antibiotics. Phenotypic screening of extended-spectrum β-lactamase (ESBL) and carbapenem resistance was followed by inhibitor-based assays to detect K. pneumoniae carbapenemase (KPC), metallo-β-lactamase (MBL), and class D oxacillinases (OXA). Among 289 Enterobacteriales, E. coli (66.4%) was the most predominant pathogen, followed by K. pneumoniae (13.8%) and P. mirabilis (8.3%). The isolates showed higher resistance to penicillins and cephalosporins (70–87%) than to non-β-lactam antimicrobials (33.2–41.5%). NDM production was a common feature among carbapenem-resistant (CR) isolates, followed by KPC and OXA. ESBL producers were susceptible to the tested new antibiotics, but NDM-positive isolates appeared resistant to these combinations. KPC-producers showed resistance to only C/T. ESBLs and carbapenemase encoding genes were located on plasmids and most of the genes were successfully transferred to recipient cells. This study revealed that MEV and CZA had significant activity against ESBL and KPC producers.
format Online
Article
Text
id pubmed-10604030
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106040302023-10-28 In Vitro Activity of New β-Lactamase Inhibitor Combinations against bla(NDM), bla(KPC), and ESBL-Producing Enterobacteriales Uropathogens Razaq, Lubna Uddin, Fakhur Ali, Shahzad Abbasi, Shah Muhammad Sohail, Muhammad Yousif, Nabila E. Abo-Dief, Hala M. El-Bahy, Zeinhom M. Antibiotics (Basel) Article Antibiotic resistance in uropathogens has increased substantially and severely affected treatment of urinary tract infections (UTIs). Lately, some new formulations, including meropenem/vaborbactam (MEV), ceftazidime/avibactam (CZA), and ceftolozane/tazobactam (C/T) have been introduced to treat infections caused by drug-resistant pathogens. This study was designed to screen Enterobacteriales isolates from UTI patients and to assess their antimicrobial resistance pattern, particularly against the mentioned (new) antibiotics. Phenotypic screening of extended-spectrum β-lactamase (ESBL) and carbapenem resistance was followed by inhibitor-based assays to detect K. pneumoniae carbapenemase (KPC), metallo-β-lactamase (MBL), and class D oxacillinases (OXA). Among 289 Enterobacteriales, E. coli (66.4%) was the most predominant pathogen, followed by K. pneumoniae (13.8%) and P. mirabilis (8.3%). The isolates showed higher resistance to penicillins and cephalosporins (70–87%) than to non-β-lactam antimicrobials (33.2–41.5%). NDM production was a common feature among carbapenem-resistant (CR) isolates, followed by KPC and OXA. ESBL producers were susceptible to the tested new antibiotics, but NDM-positive isolates appeared resistant to these combinations. KPC-producers showed resistance to only C/T. ESBLs and carbapenemase encoding genes were located on plasmids and most of the genes were successfully transferred to recipient cells. This study revealed that MEV and CZA had significant activity against ESBL and KPC producers. MDPI 2023-09-25 /pmc/articles/PMC10604030/ /pubmed/37887182 http://dx.doi.org/10.3390/antibiotics12101481 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Razaq, Lubna
Uddin, Fakhur
Ali, Shahzad
Abbasi, Shah Muhammad
Sohail, Muhammad
Yousif, Nabila E.
Abo-Dief, Hala M.
El-Bahy, Zeinhom M.
In Vitro Activity of New β-Lactamase Inhibitor Combinations against bla(NDM), bla(KPC), and ESBL-Producing Enterobacteriales Uropathogens
title In Vitro Activity of New β-Lactamase Inhibitor Combinations against bla(NDM), bla(KPC), and ESBL-Producing Enterobacteriales Uropathogens
title_full In Vitro Activity of New β-Lactamase Inhibitor Combinations against bla(NDM), bla(KPC), and ESBL-Producing Enterobacteriales Uropathogens
title_fullStr In Vitro Activity of New β-Lactamase Inhibitor Combinations against bla(NDM), bla(KPC), and ESBL-Producing Enterobacteriales Uropathogens
title_full_unstemmed In Vitro Activity of New β-Lactamase Inhibitor Combinations against bla(NDM), bla(KPC), and ESBL-Producing Enterobacteriales Uropathogens
title_short In Vitro Activity of New β-Lactamase Inhibitor Combinations against bla(NDM), bla(KPC), and ESBL-Producing Enterobacteriales Uropathogens
title_sort in vitro activity of new β-lactamase inhibitor combinations against bla(ndm), bla(kpc), and esbl-producing enterobacteriales uropathogens
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604030/
https://www.ncbi.nlm.nih.gov/pubmed/37887182
http://dx.doi.org/10.3390/antibiotics12101481
work_keys_str_mv AT razaqlubna invitroactivityofnewblactamaseinhibitorcombinationsagainstblandmblakpcandesblproducingenterobacterialesuropathogens
AT uddinfakhur invitroactivityofnewblactamaseinhibitorcombinationsagainstblandmblakpcandesblproducingenterobacterialesuropathogens
AT alishahzad invitroactivityofnewblactamaseinhibitorcombinationsagainstblandmblakpcandesblproducingenterobacterialesuropathogens
AT abbasishahmuhammad invitroactivityofnewblactamaseinhibitorcombinationsagainstblandmblakpcandesblproducingenterobacterialesuropathogens
AT sohailmuhammad invitroactivityofnewblactamaseinhibitorcombinationsagainstblandmblakpcandesblproducingenterobacterialesuropathogens
AT yousifnabilae invitroactivityofnewblactamaseinhibitorcombinationsagainstblandmblakpcandesblproducingenterobacterialesuropathogens
AT abodiefhalam invitroactivityofnewblactamaseinhibitorcombinationsagainstblandmblakpcandesblproducingenterobacterialesuropathogens
AT elbahyzeinhomm invitroactivityofnewblactamaseinhibitorcombinationsagainstblandmblakpcandesblproducingenterobacterialesuropathogens